Sustained symptom relief and safety over five years following a single intra-articular injection of 2.5[%] polyacrylamide hydrogel in patients with knee osteoarthritis
Authors' conclusion
A single IA injection of iPAAG was associated with sustained improvements in pain and function, with a favourable safety profile maintained through 5 years.
Study context
- Population
- Patients with moderate-to-severe knee osteoarthritis (OA) treated with intra-articular (IA) 2.5% iPAAG in the randomised controlled trial (RCT)58 completed 5 years
- Participants
- 91 patients
- Primary endpoint
- Change from RCT baseline in WOMAC pain (0-100)
- Follow-up
- Year 5
Methodological detailssingle-group, observational
- Single-group
- Observational
Primary result
As reported in the abstract
WOMAC pain (0-100), mean change from RCT baseline
WOMAC pain improved by a mean of −16.2 points
−16.2
95% CI −20.0 to −12.4p<0.0001
Further findings
Other WOMAC domains and patient global assessment (PGA) · year 5
- Similar improvements observed
Safety
| Outcome | Values |
|---|---|
| AEs between years 1 and 5 | iPAAG 51.6% · AEs reported 79 |
Adverse events (AEs) between years 1 and 5
- None considered related to iPAAG
Original publication
Sustained symptom relief and safety over five years following a single intra-articular injection of 2.5[%] polyacrylamide hydrogel in patients with knee osteoarthritis. Clin Exp Rheumatol. Published 15 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →